Our board brings together exceptional executives in science, healthcare, and business who are setting the new standard in healthcare.
For customer service, product information, new accounts or adverse events call: 877-3REV-NOW
1222 Demonbreun St
20th Floor
Nashville, TN 37203
Angus Russell has served as a director and Chairman of the Board since March 2014. Mr. Russell is a veteran in the global biopharmaceutical industry with more than 30 years’ experience in commercial execution, operations, and strategic acquisitions. He was the Chief Executive Officer of Shire plc, a biopharmaceutical company focused on the development of therapies for the treatment of rare and specialty conditions, from June 2008 until April 2013, Shire’s Chief Financial Officer from 1999 to 2008, and a member of its board of directors from 1999 until 2013. While CEO at Shire, Mr. Russell was also the Chair of Shire’s Leadership Team and a lead member of the Shire Management Committee, which designed and implemented the company’s immensely successful long-term business strategy. Prior to joining Shire, Mr. Russel served at AstraZeneca plc, a pharmaceutical and biologics company, most recently as VP of Corporate Finance. Mr. Russell served on the Board of Directors of Mallinckrodt from August 2014 to June 2022 and of TherapeuticsMD, Inc. from March 2015 to December 2022. Mr. Russell has also served on the board of directors of Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.), since December 2014.
Chris Nolet has served as a director since July 2019 and is Chair of the Audit Committee. Mr. Nolet is a retired audit partner at Ernst & Young. In addition to serving clients, his responsibilities include leading the West EY Life Sciences Industry Group and serving as a member of the Global EY Life Sciences Executive Leadership Group, which establishes policies and operating strategies for EY’s $2 billion practice worldwide. He serves on both the Executive Committee and Audit Committee (Chair) of the California Life Sciences Industry Association (CSLA) for the past 18 years and is a former member of the Finance & Investment Committee and Emerging Companies Section of BIO (the Biotechnology Innovation Organization). Mr. Nolet currently serves on the board of directors of Jasper Therapeutics (NASDAQ – JSPR), a biotechnology company. He also served on the board of directors of Viela Bio, Inc. until March 2021, Ambrx Biopharma Inc. until November of 2021 and PolarityTE until January of 2023. Mr. Nolet is a featured speaker at the annual Davis Polk IPO conference and has testified before congress regarding the need for FDA reform. He is a CPA (California) and member of the AIPCA and the California Society of CPAs. Additionally, Mr. Nolet served on the School of Accountancy Advisory Board at his alma mater San Diego State University, where he received his B.S. in Accounting.
Jill Beraud has served as a director since June 2019. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. She was the CEO and Co Founder of Sh’nnong Beverage Company, a business creating a line of functional beverages. She previously served as CEO of IPPOLITA, a fine jewelry company with distribution in Bergdorf Goodman, Neiman Marcus, Nordstrom, and other national retailers. Previously she held the role of Executive Vice President, Global Retail and e Commerce, for Tiffany & Co., where she was responsible for all global retail, operations, e commerce, and omni channel consumer experience. Ms. Beraud has also managed brands such as Living Proof and Starbucks/Lipton Joint Ventures and served as Global Chief Marketing Officer at PepsiCo, where she was responsible for PepsiCo’s $60 billion portfolio of food and beverage brands. She also spent 13 years at Limited Brands as Chief Marketing Officer of Victoria’s Secret, and Executive Vice President of Marketing for its broader portfolio of specialty brands, including Bath & Body Works, Henri Bendel, and Limited Stores. Further, she has a long history of board membership with iconic brands, including Levi Strauss & Co. Ms. Beraud was named to Fast Company’s “Most Creative People in Business” in 2013. She holds a B.S. in Business from Boston University and is a graduate of The Wharton School MBA program.
Vlad Coric has served as a director since March 2023. Dr. Coric is currently the Chairman and CEO of Biohaven, where he has successfully led the approval and commercialization of its Nurtec® ODT and CGRP franchise in addition to the expansion of company’s therapeutic portfolio targeting neurological and neuropsychiatric diseases. He also led Biohaven’s acquisition of its novel Kv7 channel platform and the sale of the Biohaven to Pfizer in October 2022 for total considerations of $13 billion. Previously, Dr. Coric was the Group Director, Neuroscience and Oncology Global Clinical Research, and Medical Director, Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company. He also previously served on the board of directors of Social Capital Suvretta Holdings Corp. I (DNAA) from 2021-2022 and he currently serves on the boards of directors of private biotech companies including Veradermics, Inc., Vita Therapeutics, Inc., and Pyramid Biosciences, Inc.
During his career, Dr. Coric has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor).
Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine, has published over 65 peer-reviewed publications and has lectured nationally on neurological and psychiatric disorders. He earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.
Mark J. Foley is the CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors for Glaukos Corp., (GKOS), an ophthalmic medical technology and pharmaceutical company and has served on the board of directors for SI-BONE, a medical device company. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame and is a named inventor on 17 patent applications.
Julian S. Gangolli has served as a director since July 2016. He was the President, North America of GW Pharmaceuticals Inc. and President of Greenwich Biosciences Inc., the U.S. subsidiary of GW Pharmaceuticals, spearheading the buildout of the company’s U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli is also a director of GW Pharmaceuticals PLC. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served in increasingly senior sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd. in the UK. Mr. Gangolli currently serves as a member of the board of directors of Krystal Biotech, Inc., a clinical-stage gene therapy company, and Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England.
Carey O’Connor Kolaja has served as a director since March 2021. Ms. Kolaja brings 29 years of experience as an accomplished thought leader and executive in the financial technology and payments industries. Ms. Kolaja is currently the CEO of Versapay, an accounts receivable software provider. From October 2020 to October 2022, Ms. Kolaja served as the Chief Executive Officer of AU10TIX, a global identification verification and authentication platform. Prior, Ms. Kolaja was the Global Chief Product Officer at Citi Fintech and Vice President of Global Consumer Products at PayPal. In these roles she led international teams to design, deploy, and operate global fintech and payments products. Ms. Kolaja is an author and has been featured on FOX Business, CNBC, and industry publications. She was named one of The Top 10 Women in Fintech by Fintech Magazine in 2020 and was recognized by Innotribe as one of the leading Women in Fintech bridging the gender gap. Ms. Kolaja is currently the Chairman of Everest Effect, a crisis recovery platform, and a board member for Waves for Water, an international non-profit that aims to expand the availability of clean water around the world. Ms. Kolaja holds a B.S. in Business from Indiana University Bloomington and is a graduate of the executive program of Stanford University.
Olivia C. Ware has served as a director since March 2021. Ms. Ware brings more than 21 years of experience in pharmaceutical drug development, commercialization and healthcare management. She was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing overall portfolio strategy for the company’s three BTKi molecules. She previously served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc. Ms. Ware also worked in a number of public and private biopharma firms as a private consultant and was the Chief Commercial Officer at CytRx, Inc. Previously, Ms. Ware held various leadership roles at Genentech, Inc. and played a key role in the launch of several commercial drug products, including Rituxan®, Herceptin®, Avastin® and Lucentis®. Her expertise also includes developing managed care, pricing and contracting strategy; developing marketing programs for field-based sales teams; and establishing, growing and optimizing organizations for long-term success. Ms. Ware served as a member of the board of Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company, from April 2021 to June 2022 and has served as a director of Arcellx, Inc. since May 2022. Ms. Ware holds an A.B. in Psychology from Davidson College and an M.B.A. in Finance and Marketing from the University of North Carolina at Chapel Hill.
